Cancer vaccine shows promise for patients with stage III and IV kidney cancer
A personalized neoantigen cancer vaccine led to durable disease‑free survival in all nine patients with stage III/IV clear cell renal cell carcinoma in a phase‑1 trial.
In a phase‑1 study, a personalized neoantigen vaccine was administered to nine patients with stage III/IV clear cell renal cell carcinoma after surgery. The vaccine induced a robust immune response and all patients remained disease‑free at a median follow‑up of 34.7 months, supporting further investigation of neoantigen immunotherapy in kidney cancer.
The findings suggest that a neoantigen‑based vaccine can achieve complete disease control in high‑risk kidney cancer patients, offering an alternative to current immunotherapies that only reduce recurrence risk and fail in many cases. This approach may fill a critical unmet need for durable, targeted treatment options.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Prognostic Value of the Modified Glasgow Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Nivolumab as Second-Line Therapy
- A Review of Immunotherapy in Renal Cell Carcinoma: Current Landscape and Future Directions
- EAU 2025: State-of-the-Art Lecture: Neoadjuvant Strategies in Locally Advanced Renal Cancer
- Early detection of renal cell carcinoma: a novel cell-free DNA fragmentomics‑based liquid biopsy assay
- Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)